Molecule Information
General Information of the Molecule (ID: Mol01077)
Name |
rRNA adenine N-6-methyltransferase ermG (ERMG)
,Bacillus sphaericus
|
||||
---|---|---|---|---|---|
Synonyms |
Erythromycin resistance protein; Macrolide-lincosamide-streptogramin B resistance protein
Click to Show/Hide
|
||||
Molecule Type |
Protein
|
||||
Gene Name |
ermG
|
||||
Gene ID | |||||
Sequence |
MNKVNIKDSQNFITSKYHIEKIMNCISLDEKDNIFEIGAGKGHFTAELVKRCNFVTAIEI
DSKLCEVTRNKLLNYPNYQIVNDDILKFTFPSHNPYKIFGSIPYNISTNIIRKIVFESSA TISYLIVEYGFAKRLLDTNRSLALLLMAEVDISILAKIPRYYFHPKPKVDSALIVLKRKP AKMAFKERKKYETFVMKWVNKEYEKLFTKNQFNKALKHARIYDINNISFEQFVSLFNSYK IFNG Click to Show/Hide
|
||||
Function |
Involved in erythromycin resistance.
Click to Show/Hide
|
||||
Uniprot ID | |||||
Click to Show/Hide the Complete Species Lineage | |||||
Type(s) of Resistant Mechanism of This Molecule
ADTT: Aberration of the Drug's Therapeutic Target
Drug Resistance Data Categorized by Drug
Approved Drug(s)
2 drug(s) in total
Erythromycin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Disease Class: Bacillus sphaericus infection | [1] | |||
Resistant Disease | Bacillus sphaericus infection [ICD-11: 1C4Y.4] | |||
Resistant Drug | Erythromycin | |||
Molecule Alteration | Expression | Inherence |
||
Experimental Note | Discovered Using In-vivo Testing Model | |||
In Vitro Model | Bacillus subtilis strain BD1107 | 1423 | ||
Bacillus subtilis strain BD1117 | 1423 | |||
Bacillus subtilis strain BD1146 | 1423 | |||
Bacillus subtilis strain BD1156 | 1423 | |||
Bacillus subtilis strain BD1158 | 1423 | |||
Bacillus subtilis strain BD624 | 1423 | |||
Bacillus subtilis strain BD629 | 1423 | |||
Bacillus subtilis strain BD630 | 1423 | |||
Bacillus subtilis strain CU403 | 1423 | |||
Experiment for Molecule Alteration |
Southern blotting assay | |||
Mechanism Description | One of the mechanisms of bacterial resistance to aminoglycosides is the production of aminoglycoside N-acetyl-transferase (AAC) enzymes which acetylate the amino groups present in the molecule of the aminoglycoside, preventing their interaction with the ribosome. ermG specifies a 29,000-dalton protein, the synthesis of which is induced by erythromycin. S1 nuclease mapping was used to identify the transcriptional start site. These experiments demonstrated the presence on the ermG mRNA of a 197 to 198-base leader. |
Macrolides
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Disease Class: Bacillus sphaericus infection | [1] | |||
Resistant Disease | Bacillus sphaericus infection [ICD-11: 1C4Y.4] | |||
Resistant Drug | Macrolides | |||
Molecule Alteration | Expression | Inherence |
||
Experimental Note | Discovered Using In-vivo Testing Model | |||
In Vitro Model | Bacillus subtilis strain BD1107 | 1423 | ||
Bacillus subtilis strain BD1117 | 1423 | |||
Bacillus subtilis strain BD1146 | 1423 | |||
Bacillus subtilis strain BD1156 | 1423 | |||
Bacillus subtilis strain BD1158 | 1423 | |||
Bacillus subtilis strain BD624 | 1423 | |||
Bacillus subtilis strain BD629 | 1423 | |||
Bacillus subtilis strain BD630 | 1423 | |||
Bacillus subtilis strain CU403 | 1423 | |||
Experiment for Molecule Alteration |
Southern blotting assay | |||
Mechanism Description | One of the mechanisms of bacterial resistance to aminoglycosides is the production of aminoglycoside N-acetyl-transferase (AAC) enzymes which acetylate the amino groups present in the molecule of the aminoglycoside, preventing their interaction with the ribosome. ermG specifies a 29,000-dalton protein, the synthesis of which is induced by erythromycin. S1 nuclease mapping was used to identify the transcriptional start site. These experiments demonstrated the presence on the ermG mRNA of a 197 to 198-base leader. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.